Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Pazdur

Showing results (81-90 of 468) with videos related to

Pageof 47
Sort By:
The Oncologist|February 6, 2009
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumorsMartin H Cohen, Ann Farrell, Robert Justice, et al.
Regulatory Toxicology and Pharmacology : RTP|March 9, 2016
An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugsJohn K Leighton, Haleh Saber, Gregory Reaman, et al.
The New England Journal of Medicine|October 8, 2021
The Drug-Dosing Conundrum in Oncology - When Less Is MoreMirat Shah, Atiqur Rahman, Marc R Theoret, et al.
American Journal of Hematology|March 5, 2010
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney diseaseMin Lu, Martin H Cohen, Dwaine Rieves, et al.
Cancer|May 13, 2017
Regulatory considerations on endpoints in ovarian cancer drug developmentSanjeeve Balasubramaniam, Geoffrey S Kim, Amy E McKee, et al.
The Oncologist|July 1, 2008
FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphomaMartin H Cohen, John R Johnson, Robert Justice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Regulatory approvals of pediatric oncology drugs: previous experience and new initiativesSteven Hirschfeld, Peter T C Ho, Malcolm Smith, et al.
The Oncologist|October 13, 2004
FDA drug approval summaries: pemetrexed (Alimta)Maitreyee Hazarika, Robert M White, John R Johnson, et al.
Journal of the National Cancer Institute|October 21, 2004
Accelerated approval of oncology products: a decade of experienceRamzi Dagher, John Johnson, Grant Williams, et al.
The Oncologist|May 31, 2012
Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumorsMartin H Cohen, John R Johnson, Robert Justice, et al.
Pageof 47

Showing results (81-90 of 468) with videos related to

Sort By:
Pageof 47
The Oncologist|February 6, 2009
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumorsMartin H Cohen, Ann Farrell, Robert Justice, et al.
Regulatory Toxicology and Pharmacology : RTP|March 9, 2016
An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugsJohn K Leighton, Haleh Saber, Gregory Reaman, et al.
The New England Journal of Medicine|October 8, 2021
The Drug-Dosing Conundrum in Oncology - When Less Is MoreMirat Shah, Atiqur Rahman, Marc R Theoret, et al.
American Journal of Hematology|March 5, 2010
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney diseaseMin Lu, Martin H Cohen, Dwaine Rieves, et al.
Cancer|May 13, 2017
Regulatory considerations on endpoints in ovarian cancer drug developmentSanjeeve Balasubramaniam, Geoffrey S Kim, Amy E McKee, et al.
The Oncologist|July 1, 2008
FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphomaMartin H Cohen, John R Johnson, Robert Justice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Regulatory approvals of pediatric oncology drugs: previous experience and new initiativesSteven Hirschfeld, Peter T C Ho, Malcolm Smith, et al.
The Oncologist|October 13, 2004
FDA drug approval summaries: pemetrexed (Alimta)Maitreyee Hazarika, Robert M White, John R Johnson, et al.
Journal of the National Cancer Institute|October 21, 2004
Accelerated approval of oncology products: a decade of experienceRamzi Dagher, John Johnson, Grant Williams, et al.
The Oncologist|May 31, 2012
Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumorsMartin H Cohen, John R Johnson, Robert Justice, et al.
Pageof 47